Literature DB >> 8424307

"Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy.

A Vázquez1, F J Jiménez-Jiménez, P García-Ruiz, D García-Urra.   

Abstract

A series of 31 Parkinson's disease (PD) patients suffering from panic attacks (PA), late in the evolution of their disease, was analyzed from a group of 131 levodopa-treated PD patients. We found that many of motor, sensory, and vegetative symptoms, previously described as complicating phenomena in PD, constituted some of the symptoms of panic disorders. Comparing PA series with the series of PD patients who did not complain of PA, we discovered a clear-cut relationship of PA with the presence of standing/gait troubles (p < 0.001), depression (p < 0.001), and dyskinesias/fluctuations (p < 0.001). The patients of the PA series also presented a more precocious age of PD onset, were put on levodopa therapy earlier, and needed to be treated with higher doses of levodopa than the patients without PA. Finally, we hypothesize that PA could be considered to be a sort of abstinence syndrome from levodopa, because they appears mostly (90.3%) in the OFF phase of fluctuations, and are relieved administering new doses of levodopa or dopaminergic agonists. Nevertheless, we suggest PA are not directly related to the pharmacological properties of levodopa, but to alterations of the noradrenergic systems in the CNS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424307

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  23 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  The association between clinically relevant anxiety and other non-motor symptoms in Parkinson's disease.

Authors:  Si-Ming Jiang; Yong-Sheng Yuan; Qing Tong; Li Zhang; Qin-Rong Xu; Jian Ding; Ke-Zhong Zhang
Journal:  Neurol Sci       Date:  2015-07-08       Impact factor: 3.307

Review 3.  Neuropsychiatric aspects of Parkinson's disease: recent advances.

Authors:  Laura Marsh; Ariel Berk
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

Review 4.  Anxiety in Parkinson's disease: identification and management.

Authors:  Jack J Chen; Laura Marsh
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

Review 5.  Anxiety and medical disorders.

Authors:  Jacqueline E Muller; Liezl Koen; Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 6.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

7.  Familial aggregation of panic disturbances in Parkinson's disease.

Authors:  Gregory M Pontone; Justin Palanci; O Joseph Bienvenu; Kung-Yee Liang; Gerald Nestadt; Peter V Rabins; James R Williams; Laura Marsh
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

8.  Delusions in Parkinson's Disease: A Systematic Review of Published Cases.

Authors:  Nicola Warren; Cullen O'Gorman; Zena Hume; Steve Kisely; Dan Siskind
Journal:  Neuropsychol Rev       Date:  2018-08-02       Impact factor: 7.444

Review 9.  Psychiatric symptoms in Parkinson's disease.

Authors:  Frank Schneider; Astrid Althaus; Volker Backes; Richard Dodel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

Review 10.  Parkinson's disease and anxiety.

Authors:  K Walsh; G Bennett
Journal:  Postgrad Med J       Date:  2001-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.